SCHEMBL8624765

SCHEMBL8624765

CCCc1cccc(OC/C(C)=C/CCCC(P(=O)(O)O)S(=O)(=O)O)c1

nearest known ligand 0.45

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 4/20 0.42
FDFT1 P37268 6/20 0.42
PTGIR P43119 1/20 0.41
PPARG P37231 2/20 0.41
GGPS1 O95749 2/20 0.37
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA7 P43166 1/20 0.35
CA9 Q16790 1/20 0.35
CA14 Q9ULX7 1/20 0.35
CYP2D6 P10635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8624770 1.00 PPARA (0.42) PPARAFDFT1PTGIRPPARGGGPS1
SCHEMBL8618472 0.88 S1PR1 (0.40) FDFT1
SCHEMBL8618467 0.88 S1PR1 (0.40) FDFT1
SCHEMBL8623006 0.86 KMT2A (0.43)
SCHEMBL8623000 0.86 KMT2A (0.43)
SCHEMBL27415461 0.85 KMT2A (0.42)
SCHEMBL8618608 0.84 BTN3A1 (0.37)
SCHEMBL8624208 0.82 MTNR1A (0.41) FDFT1CA1CA2CA7CA9
SCHEMBL8624202 0.82 MTNR1A (0.41) FDFT1CA1CA2CA7CA9
SCHEMBL8623165 0.80 FDFT1 (0.62) FDFT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5712396-A PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS MAGNIN DAVID R (US) 1998-01-27 US claimed
EP-0595635-A1 Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors E.R. Squibb & Sons, Inc. (US) 1994-05-04 EP claimed
US-5712396-A PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS MAGNIN DAVID R (US) 1998-01-27 US disclosed
US-5470845-A Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia BRISTOL-MYERS SQUIBB COMPANY (US) 1995-11-28 US disclosed
EP-0595635-A1 Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors E.R. Squibb & Sons, Inc. (US) 1994-05-04 EP disclosed